Press "Enter" to skip to content

Orion Biotech Opportunities Corp Announced its IPO Earnings

By Willie Wise on May 14, 2021

Orion Biotech Opportunities Corp. announced the pricing of its initial public offering of 20,000,000 units for $10.00 per unit. The units will be listed on The Nasdaq Capital Market LLC and traded under the symbol “ORIAU” beginning May 13, 2021.

Each unit consists of one of the Orion Biotech Opportunities Corp Class A shares and one-fifth of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share. Once the securities including the units start separate trading, the Class A shares and warrants are expected to be listed on the Nasdaq under the symbols “ORIA” and “ORIAW”, respectively.

Cantor Fitzgerald & Co. is acting as the only book-running manager for the offering. The Company has awarded the underwriter a 45-day option to purchase up to 3,000,000 extra units to cover over-allotments. The offering is expected to close on May 17, 2021. It is subject to customary closing conditions. The offering is made only using a prospectus. Copies of the prospectus may be obtained, when available, from Cantor Fitzgerald & Co.

An enrollment announcement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission on May 12, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

Published in Biotechnology and News

Willie Wise

Backed by a strong educational background with a degree in Biotechnology, Greenville Technical College, Willie D. Wise is an asset to The Healthcare News and is rightfully placed as the Chief Editor, owing to his vast experience in technical writing, marketing, and strategic planning. To hone his job skills in journalism, Wise has also completed a degree course in journalism from the University of South Carolina-Columbia. He is highly skilled with the art of news presentation and is adept in an editorial role with excellent time management and leadership qualities at his disposal. He ensures the best delivery from his team of writers and ensures excellent performance by his team. Besides his current job as the editor-in-chief at The Healthcare News, he is a regular writer for the biotechnology category. Given his intense interest in the field, his core career centers around writing which he does with complete dexterity. As a writer, he ensures appropriate title selection besides developing authentic, market-relevant content ideal for business discretion and also to suit promotional and marketing strategies of TheHealthcareNews. His writing style not only remains informative but also is high on lucidity to entice reader focus for longer. Crude facts and statistical details are also presented simplistically to connect with readers' grasping capabilities.

More from BiotechnologyMore posts in Biotechnology »
More from NewsMore posts in News »

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *